Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical- stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company's d ...

Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership role ...

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 44 Annual J.P. Morgan Healthcare Conference. The conference will take place January 12- 15, 2026, in San Francisco, California. Details are as follows: About Viking Therapeutics ...

Core Insights - The obesity drugs market is experiencing a revival after a period of consolidation that began in early 2024, attracting healthcare investors since the "great market rotation" themes of Q4 2025 [1] Group 1: Market Trends - The healthcare sector is seeing renewed interest from investors, particularly in obesity drugs, following a consolidation phase [1] - The "great market rotation" in Q4 2025 has contributed to this renewed investor enthusiasm [1] Group 2: Investment Strategy - The company focuses on identifying attractive risk/reward opportunities that are supported by strong price action, aiming to generate alpha above the S&P 500 [1] - The investment approach combines price action analysis with fundamental analysis, avoiding overhyped stocks while targeting undervalued stocks with recovery potential [1] - The investment group specializes in high-potential opportunities across various sectors, emphasizing stocks with strong growth potential and appealing turnaround plays [1]

Core Insights - Viking Therapeutics (VKTX) is advancing its late-stage obesity candidate VK2735, a dual GLP-1 and GIP receptor agonist, through multiple clinical studies for obesity treatment [1][2] Group 1: Clinical Development - VKTX is conducting two late-stage studies, VANQUISH-1 and VANQUISH-2, evaluating the SC version of VK2735 over a 78-week treatment period [2] - Enrollment in the VANQUISH-1 study has been completed with approximately 4,650 patients, exceeding the target of 4,500 patients, while nearly 1,100 patients are expected to be enrolled in VANQUISH-2 by the end of this quarter [3][11] Group 2: Market Dynamics - The rapid enrollment in VKTX's studies indicates strong demand for VK2735, reflecting high patient and physician enthusiasm, which could lead to significant commercial potential if the drug proves effective [4] - The obesity market in the U.S. is projected to reach $100 billion by 2030, with Eli Lilly and Novo Nordisk already generating substantial revenue from their obesity drugs [5] Group 3: Competitive Landscape - Novo Nordisk has received FDA approval for the oral version of Wegovy, enhancing patient adherence due to its convenience, while Eli Lilly is pursuing approval for its oral candidate, orforglipron [6][7] - Both companies are investing in next-generation obesity therapies, with Eli Lilly developing retatrutide and Novo Nordisk advancing amycretin, indicating a competitive landscape that is evolving rapidly [8][9] Group 4: Financial Performance - VKTX shares have underperformed the industry over the past year, trading at a premium with a price-to-book value (P/B) ratio of 5.58 compared to the industry average of 3.61 [12][14] - Estimates for VKTX's loss per share for 2025 and 2026 have widened recently, indicating potential challenges ahead [16]

Group 1 - Stone Fox Capital is a Registered Investment Advisor (RIA) based in Oklahoma, led by Mark Holder, a CPA with extensive experience in investing and portfolio management [1] - Mark Holder has 30 years of investing experience, including 15 years as a portfolio manager, and leads the investing group Out Fox The Street [1] - The investing group provides stock picks, deep research, model portfolios, daily updates, real-time alerts, and community chat for readers [1] Group 2 - The article does not contain any stock, option, or similar derivative positions in the companies mentioned, but there is a potential for initiating a long position in VKTX within the next 72 hours [2] - The information is intended for informational purposes only and should not be considered as a solicitation to buy or sell securities [3] - Past performance is not indicative of future results, and no specific investment recommendations are provided [4]

Core Viewpoint - Stone Fox Capital is an RIA based in Oklahoma, led by Mark Holder, a CPA with extensive experience in investing and portfolio management [1] Group 1: Company Overview - Stone Fox Capital provides investment research and analysis services, focusing on uncovering potential multibaggers while managing portfolio risk through diversification [1] - Mark Holder has 30 years of investing experience, including 15 years as a portfolio manager, and leads the investing group Out Fox The Street [1] Group 2: Services Offered - The company offers various model portfolios, stock picks with identifiable catalysts, daily updates, and real-time alerts [1] - Subscribers have access to community chat and direct communication with Mark for inquiries [1]

Key Points Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges. 10 stocks we like better than Viking Therapeutics › One great way to earn above-average market returns is to identify stocks that aren't performing well -- even as broader equities are moving higher -- but could eventually rebound. There are plenty of candidates to pick from as the stock market closes out another solid year. Two beaten-down stocks worth considering for ...

Viking Therapeutics (VKTX) may be flying under the radar, but it could soon become one of the most closely watched biotech stories heading into 2026. It is a high-risk, high-reward biotech company trying to build the next generation of obesity treatments. Over the past year, the company has made significant strides in advancing its lead obesity treatment, VK2735, while strengthening its clinical pipeline and positioning its balance sheet to support multiple future catalysts. Let’s find out if it is a goo ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...